Benutzerspezifische Werkzeuge

Klinische Studien

Klinische Studien

Für Patienten

In unserem Studienzentrum liegt der Schwerpunkt auf Studien der Phase II und III.

  • aktuelle klinische Studien zu folgenden Indikationen:
Prostatakarzinom

A confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unenhanced MRI in reference to histopathology in newly-diagnosed prostate cancer (PCA) patients, scheduled for radical prostatectomy (RP) wih extended pelvic lymph node dissection (ePLND)

SPL-01-001

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

PRIMORDIUM

Clinical study to prove the positive healthcare effect of the Uroletics® app in patients with prostate cancer 

EUPROS
Urothelkarzinom (Harnblase und oberer Harntrakt)

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD
(padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade
Upper Tract Urothelial Cancer

CLIN2001 UCM301

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in
Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants
With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving
Radical Cystectomy

SunRISe-2
Nierenzellkarzinom

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

MK6482-022

A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

BO43936

weitere Informationen finden Sie unter: ClinicalTrials.gov

Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.

Kontakt:

Platzhalter Bild

Pit Raupach

Leitender Studienkoordinator

+49- 0351 458-4425 +49- 0351 458-7280